Effect of alvimopan and codeine on gastrointestinal transit: A randomized controlled study

Jonathan Gonenne, Michael Camilleri, Irene Ferber, Duane Burton, Kari Baxter, Kian Keyashian, Joseph Foss, Bruce Wallin, Wei Du, Alan R. Zinsmeister

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Background & Aims: Opiate bowel dysfunction is a significant clinical problem. Our aim was to evaluate the ability of a peripheral μ-opioid antagonist, alvimopan, to reverse the effect of codeine on gastric, small-bowel, and colonic transit time in healthy volunteers. Methods: Seventy-four healthy participants (43 women) were randomized in a double-blind, placebo-controlled manner to 1 of 4 groups: alvimopan 12 mg twice daily in the presence and absence of codeine sulfate 30 mg 4 times/day, or codeine or placebo alone. Gastric emptying, small-bowel, and colonic transit were measured by scintigraphy using a 99m-labeled technetium egg meal and 111-labeled indium charcoal delivered to the proximal colon via a delayed-release capsule. The primary end points for colonic transit were geometric center of the colonic counts at 24 hours and time for 50% ascending colon emptying. Analysis of covariance was used to assess the significance of the primary and secondary end points. Results: Codeine delayed gastric, small-bowel, proximal, and overall colonic transit (P < .05). Alvimopan reversed codeine's effect on small bowel and colon (ascending colon and overall colonic transit). Alvimopan also accelerated overall colonic transit compared with placebo. Thus, the mean colonic geometric center at 24 hours was 2.33 with placebo/placebo, 3.25 with alvimopan/placebo (P < .05), 1.5 with placebo/codeine (P < .05), and 2.63 with alvimopan/codeine. Alvimopan did not reverse codeine's delay of gastric emptying. Conclusions: Alvimopan reverses codeine's inhibitory effect on small-bowel and colon transit and has potential for treatment of opiate bowel dysfunction. Alvimopan alone accelerates colonic transit, suggesting that μ-opiate mechanisms participate in the physiologic control of colonic transit.

Original languageEnglish (US)
Pages (from-to)784-791
Number of pages8
JournalClinical Gastroenterology and Hepatology
Volume3
Issue number8
DOIs
StatePublished - Aug 2005

Fingerprint

alvimopan
Gastrointestinal Transit
Codeine
Opiate Alkaloids
Placebos
Ascending Colon
Colon
Gastric Emptying
Stomach
Healthy Volunteers
Indium
Narcotic Antagonists
Charcoal
Technetium

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Effect of alvimopan and codeine on gastrointestinal transit : A randomized controlled study. / Gonenne, Jonathan; Camilleri, Michael; Ferber, Irene; Burton, Duane; Baxter, Kari; Keyashian, Kian; Foss, Joseph; Wallin, Bruce; Du, Wei; Zinsmeister, Alan R.

In: Clinical Gastroenterology and Hepatology, Vol. 3, No. 8, 08.2005, p. 784-791.

Research output: Contribution to journalArticle

Gonenne, J, Camilleri, M, Ferber, I, Burton, D, Baxter, K, Keyashian, K, Foss, J, Wallin, B, Du, W & Zinsmeister, AR 2005, 'Effect of alvimopan and codeine on gastrointestinal transit: A randomized controlled study', Clinical Gastroenterology and Hepatology, vol. 3, no. 8, pp. 784-791. https://doi.org/10.1016/S1542-3565(05)00434-9
Gonenne, Jonathan ; Camilleri, Michael ; Ferber, Irene ; Burton, Duane ; Baxter, Kari ; Keyashian, Kian ; Foss, Joseph ; Wallin, Bruce ; Du, Wei ; Zinsmeister, Alan R. / Effect of alvimopan and codeine on gastrointestinal transit : A randomized controlled study. In: Clinical Gastroenterology and Hepatology. 2005 ; Vol. 3, No. 8. pp. 784-791.
@article{5b1696d9e7934c17b65fbcf753b4dc26,
title = "Effect of alvimopan and codeine on gastrointestinal transit: A randomized controlled study",
abstract = "Background & Aims: Opiate bowel dysfunction is a significant clinical problem. Our aim was to evaluate the ability of a peripheral μ-opioid antagonist, alvimopan, to reverse the effect of codeine on gastric, small-bowel, and colonic transit time in healthy volunteers. Methods: Seventy-four healthy participants (43 women) were randomized in a double-blind, placebo-controlled manner to 1 of 4 groups: alvimopan 12 mg twice daily in the presence and absence of codeine sulfate 30 mg 4 times/day, or codeine or placebo alone. Gastric emptying, small-bowel, and colonic transit were measured by scintigraphy using a 99m-labeled technetium egg meal and 111-labeled indium charcoal delivered to the proximal colon via a delayed-release capsule. The primary end points for colonic transit were geometric center of the colonic counts at 24 hours and time for 50{\%} ascending colon emptying. Analysis of covariance was used to assess the significance of the primary and secondary end points. Results: Codeine delayed gastric, small-bowel, proximal, and overall colonic transit (P < .05). Alvimopan reversed codeine's effect on small bowel and colon (ascending colon and overall colonic transit). Alvimopan also accelerated overall colonic transit compared with placebo. Thus, the mean colonic geometric center at 24 hours was 2.33 with placebo/placebo, 3.25 with alvimopan/placebo (P < .05), 1.5 with placebo/codeine (P < .05), and 2.63 with alvimopan/codeine. Alvimopan did not reverse codeine's delay of gastric emptying. Conclusions: Alvimopan reverses codeine's inhibitory effect on small-bowel and colon transit and has potential for treatment of opiate bowel dysfunction. Alvimopan alone accelerates colonic transit, suggesting that μ-opiate mechanisms participate in the physiologic control of colonic transit.",
author = "Jonathan Gonenne and Michael Camilleri and Irene Ferber and Duane Burton and Kari Baxter and Kian Keyashian and Joseph Foss and Bruce Wallin and Wei Du and Zinsmeister, {Alan R.}",
year = "2005",
month = "8",
doi = "10.1016/S1542-3565(05)00434-9",
language = "English (US)",
volume = "3",
pages = "784--791",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Effect of alvimopan and codeine on gastrointestinal transit

T2 - A randomized controlled study

AU - Gonenne, Jonathan

AU - Camilleri, Michael

AU - Ferber, Irene

AU - Burton, Duane

AU - Baxter, Kari

AU - Keyashian, Kian

AU - Foss, Joseph

AU - Wallin, Bruce

AU - Du, Wei

AU - Zinsmeister, Alan R.

PY - 2005/8

Y1 - 2005/8

N2 - Background & Aims: Opiate bowel dysfunction is a significant clinical problem. Our aim was to evaluate the ability of a peripheral μ-opioid antagonist, alvimopan, to reverse the effect of codeine on gastric, small-bowel, and colonic transit time in healthy volunteers. Methods: Seventy-four healthy participants (43 women) were randomized in a double-blind, placebo-controlled manner to 1 of 4 groups: alvimopan 12 mg twice daily in the presence and absence of codeine sulfate 30 mg 4 times/day, or codeine or placebo alone. Gastric emptying, small-bowel, and colonic transit were measured by scintigraphy using a 99m-labeled technetium egg meal and 111-labeled indium charcoal delivered to the proximal colon via a delayed-release capsule. The primary end points for colonic transit were geometric center of the colonic counts at 24 hours and time for 50% ascending colon emptying. Analysis of covariance was used to assess the significance of the primary and secondary end points. Results: Codeine delayed gastric, small-bowel, proximal, and overall colonic transit (P < .05). Alvimopan reversed codeine's effect on small bowel and colon (ascending colon and overall colonic transit). Alvimopan also accelerated overall colonic transit compared with placebo. Thus, the mean colonic geometric center at 24 hours was 2.33 with placebo/placebo, 3.25 with alvimopan/placebo (P < .05), 1.5 with placebo/codeine (P < .05), and 2.63 with alvimopan/codeine. Alvimopan did not reverse codeine's delay of gastric emptying. Conclusions: Alvimopan reverses codeine's inhibitory effect on small-bowel and colon transit and has potential for treatment of opiate bowel dysfunction. Alvimopan alone accelerates colonic transit, suggesting that μ-opiate mechanisms participate in the physiologic control of colonic transit.

AB - Background & Aims: Opiate bowel dysfunction is a significant clinical problem. Our aim was to evaluate the ability of a peripheral μ-opioid antagonist, alvimopan, to reverse the effect of codeine on gastric, small-bowel, and colonic transit time in healthy volunteers. Methods: Seventy-four healthy participants (43 women) were randomized in a double-blind, placebo-controlled manner to 1 of 4 groups: alvimopan 12 mg twice daily in the presence and absence of codeine sulfate 30 mg 4 times/day, or codeine or placebo alone. Gastric emptying, small-bowel, and colonic transit were measured by scintigraphy using a 99m-labeled technetium egg meal and 111-labeled indium charcoal delivered to the proximal colon via a delayed-release capsule. The primary end points for colonic transit were geometric center of the colonic counts at 24 hours and time for 50% ascending colon emptying. Analysis of covariance was used to assess the significance of the primary and secondary end points. Results: Codeine delayed gastric, small-bowel, proximal, and overall colonic transit (P < .05). Alvimopan reversed codeine's effect on small bowel and colon (ascending colon and overall colonic transit). Alvimopan also accelerated overall colonic transit compared with placebo. Thus, the mean colonic geometric center at 24 hours was 2.33 with placebo/placebo, 3.25 with alvimopan/placebo (P < .05), 1.5 with placebo/codeine (P < .05), and 2.63 with alvimopan/codeine. Alvimopan did not reverse codeine's delay of gastric emptying. Conclusions: Alvimopan reverses codeine's inhibitory effect on small-bowel and colon transit and has potential for treatment of opiate bowel dysfunction. Alvimopan alone accelerates colonic transit, suggesting that μ-opiate mechanisms participate in the physiologic control of colonic transit.

UR - http://www.scopus.com/inward/record.url?scp=23644447886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23644447886&partnerID=8YFLogxK

U2 - 10.1016/S1542-3565(05)00434-9

DO - 10.1016/S1542-3565(05)00434-9

M3 - Article

C2 - 16234007

AN - SCOPUS:23644447886

VL - 3

SP - 784

EP - 791

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 8

ER -